Translational Research Services
Harnessing fresh human samples to provide unrivalled translational insights
Accelerating Drug Development Through Translational Research
Synexa’s translational research service is dedicated to understanding candidate therapeutics and biomarker data to generate clinically relevant data, using fresh human samples from both healthy and diseased populations.
Utilising a broad range of technologies, Synexa assesses candidate drugs in clinically relevant samples from a broad range of therapeutic indications, delivering critical insights including the safety profile, efficacy and mechanism of action, providing the assurance needed to confidently progress into clinical trials.
Providing Unrivalled Access To Fresh Human Biological Samples
Synexa’s clinical network is extensive; we collaborate with a wide range of clinicians who provide fresh (healthy and disease-matched) human biological samples from patients in support of clinical studies. Samples come with full clinical metadata – access well-characterised populations with disease-relevant heterogeneity.
Ethical integrity is the foundation of every study we support. All patients provide informed consent, and we follow stringent national and international guidelines throughout. Our team manages the full ethics protocol development and submission process.
Oncology
Disease access:
- Acute Myeloid
- Leukaemia
- Chronic Lymphocytic Leukaemia
- Chronic myeloid leukaemia
- Non-Hodgkin’s lymphoma
- Hodgkin’s lymphoma
- Ovarian cancer
Sample matrices:
- Peripheral blood/PBMCs
- Serum & plasma
- Ascites
- Biopsies where possible
- Haematological
Neurology
Disease access:
- Multiple sclerosis
- Parkinson’s disease
- Alzheimer’s disease
- Neuroinflammatory conditions
- Neuropsychiatric conditions
Sample matrices:
- Peripheral blood/PBMCs
- Serum & plasma
- CSF where possible
- CNS-immune axis focus
Rheumatology
Disease access:
- Rheumatoid arthritis
- Systemic lupus erythematosus
- Cutaneous lupus
- Psoriatic arthritis
- Myasthenia Gravis
Sample matrices:
- Peripheral blood/PBMCs
- Serum & plasma
- Urine
- Synovial fluid
- Tissue biopsies
Dermatology
Disease access:
- Atopic dermatitis
- Psoriasis
- Hidradenitis suppurativa
- Lichen planus
- Vitiligo
- Pemphigoid
Sample matrices:
- Fresh skin biopsies (lesional & non-lesional)
- Peripheral blood/PBMCs
- Serum & plasma
- Harpera microbiopsy
- Established skin biopsy workflows
Gastroenterology & Others
Disease access:
- IBD: Crohn’s and ulcerative colitis
- Fibrotic conditions
- Respiratory
- Opthalmology
Sample matrices:
- Peripheral blood/PBMCs
- Colon biopsies
- Serum & plasma
- Bronchoalveolar lavage fluid
- Active expansion
- Aqueous and vitreous humour
- Retinal biopsies
- Fibrovascular membranes
Design Your Translational Study
- Consultation and protocol design
Specialised team with a deep understanding of disease mechanisms and treatment landscape - Experimental design
Flexibility and customisation, each solution is tailored to meet the unique needs of a therapeutic candidate - Ethical approval and sample collection
We collaborate with a large network of clinical sites to obtain ethically sourced, fresh patient samples from diverse populations with full clinical data collection - Data generation and analysis
Integrated with our advanced analytical platforms, we generate robust, actionable datasets that mirror real-life patient responses - Decision making and integration with clinical development
Rapid data processing and interim reports to inform decision making and potential trial adaptations, incorporating biomarker signatures of response
Unlock Key Insights with Synexa's Translational Research Services
Early Efficacy & Safety Insights
Assess drug efficacy, safety and pharmacodynamics before clinical entry. Confirm target validation, engagement and mechanism of action to improve confidence in candidate selection.
Indication Prioritisation
Evaluate therapeutic potential across multiple disease areas to identify the most promising indications and refine development strategy.
Competitive Benchmarking
Compare lead candidates against marketed therapies and competitor compounds to understand differentiation and positioning.
Rapid Iteration
Accelerate development timelines through efficient testing cycles, enabling faster optimisation of drug candidates and biomarker strategies.
Translational Science FAQs
What is translational science in the context of biomarker research?
In biomarker research, translational science refers to the process of turning laboratory-based insights into clinically meaningful outcomes. At Synexa, this involves designing and deploying fit-for-purpose assays that link molecular signatures with disease mechanisms, patient stratification strategies, and therapeutic responses – particularly in immunology and rare diseases.
How does Synexa's translational service work?
Synexa’s translational approach begins with understanding the clinical question and therapeutic context. From there, we design mechanistically relevant biomarker strategies, selecting or developing fit-for-purpose assays that generate data aligned with trial objectives. Using a range of advanced platforms, including flow cytometry, MSD, and genomics, we analyse biological samples to identify meaningful patterns. The resulting data are interpreted by our scientific teams to inform patient stratification, target engagement, and drug mechanism-of-action insights, ultimately bridging the gap between discovery science and clinical outcomes.
Where do the samples Synexa utilises for translational studies come from?
Synexa Life Sciences sources ethically obtained, fresh human samples through a trusted global clinical network. These samples come from both healthy individuals and patients across various disease indications and at different stages of disease progression. Each sample is accompanied by relevant clinical data and is selected to support biomarker discovery, target engagement, and proof-of-biology studies. Our access to diverse patient populations and sample matrices enables precise profiling and translational insights. With world-class clinical experts and key opinion leaders guiding our approach, Synexa ensures scientific certainty and logistical excellence in every study.
What platforms and technologies are used in Synexa’s translational biomarker services?
Synexa leverages a broad range of platforms including flow cytometry, MSD, qPCR, and high-resolution mass spectrometry to generate mechanistically relevant biomarker data. All assays are developed with clinical context in mind, ensuring alignment with regulatory and therapeutic goals.
How does Synexa support patient stratification in clinical trials?
Synexa applies deep immunophenotyping, multi-omic profiling, and customised biomarker panels to identify sub-populations most likely to respond to therapy. This enables data-driven patient stratification strategies that enhance trial success and accelerate precision medicine approaches.
More on Translational Solutions
Bridging the Gap: Translating Animal Model Findings to Clinical Oncology Breakthroughs
Why The Future Of Precision Medicine Will Be Defined By The Quality And Strategy Of Biomarker Signatures
Why The Future Of Precision Medicine Will Be Defined By The Quality And Strategy Of Biomarker Signatures
Bridging the Gap: Translating Animal Model Findings to Clinical Oncology Breakthroughs
Improving the quality of human health
Contact us
Discuss biomarker and bioanalytical solutions to accelerate your therapeutic pipeline
